Patient-centered Outcomes in Breast Cancer: Description of EQ-5D-5L and EORTC-QLQ-BR23 Measurements in Real-world Data and Their Association With Survival

Monteiro, Mariana Ribeiro; Nunes, N.C.C.; Crespo, J.; Abrahão, Ana Beatriz Kinupe; Buscacio, G.; Lerner, L.C.C.; Sermoud, L.; Arakelian, R.; Piotto, G.; Lemos, Carolina; Campos, Ricardo Robless; Victorino, D.; Andrade, Perla; Ferreira, T.A.V.; Pecoraro, J.P.; Meton, F.; Gaui, M.F.; Araujo, Luiz H.

doi:10.1016/j.clon.2022.05.015

Cited by 6 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By contrast, not many patients had problems involving self-care (12.0%). These results were in line with the findings of numerous previous studies in Brazil, China, Ethiopia, Korea, and Singapore [ 13 , 14 , 22 – 26 ]. However, anxiety/depression was the most common health issue among breast cancer patients in India and Indonesia, followed by pain/discomfort [ 27 , 28 ].…”

Section: Discussionsupporting

confidence: 93%

“…It is perfectly understandable that the severity of these health dimensions among the former was greater than that of the latter. Two studies in Brazil and China reported similar results when patients with metastatic breast cancer suffered from more health problems than the non-metastatic group [ 14 , 24 ]. However, in these two studies, the differences were statistically significant in all five dimensions.…”

Section: Discussionmentioning

confidence: 80%

“…Our findings were similar to the results of a study in the United Kingdom (patients receiving treatment for metastatic breast cancer: 65.82 and patients currently undergoing treatment for early breast cancer: 72.74) [ 15 ]. In comparison with non-metastatic breast cancer patients, the higher EQ-VAS scores of patients with metastatic breast cancer were also reported in Brazil, China, India, and Indonesia [ 14 , 23 , 24 , 27 , 28 ].…”

Section: Discussionmentioning

confidence: 89%

“…However, most of them focused on the general population of breast cancer patients receiving various types of treatment therapies (such as surgery, radiotherapy, and chemotherapy). The number of studies for HER2-positive breast cancer patients (especially patients undergoing systemic treatment) is negligible [ 14 , 15 ]. In addition, the treatment costs of HER2-targeted drugs are exorbitant.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study

Luu,

Dinh,

Tran

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer may have poor prognoses and short overall and disease-free survival. Most previous studies focused on assessing the quality of life and health-state utility of the general population of breast cancer patients. The number of studies for HER2-positive breast cancer patients is negligible. This study investigated the health-state utility and its associated factors among Vietnamese patients with HER2-positive breast cancer. Methods We conducted face-to-face interviews with 301 HER2-positive breast cancer patients to collect data. Their health-state utility was measured via the EQ-5D-5L instrument. The Mann-Whitney U and Kruskal-Wallis tests were employed to compare the differences in utility scores between two groups and among three groups or more, respectively. Factors associated with patients’ heath-state utility were identified via Tobit regression models. Results Pain/discomfort (56.1%) and anxiety/depression (39.5%) were the two issues that patients suffered from the most, especially among metastatic breast cancer patients. The severity of distress (depression, anxiety, and stress) in patients was relatively mild. Of 301 patients, their average utility score was 0.86±0.17 (range: 0.03–1.00), and the average EQ-visual analogue scale (VAS) score was 69.12±12.60 (range: 30–100). These figures were 0.79±0.21 and 65.20±13.20 for 102 metastatic breast cancer patients, significantly lower than those of 199 non-metastatic cancer patients (0.89±0.13 and 71.13±11.78) (p<0.001), respectively. Lower health-state utility scores were significantly associated with older age (p = 0.002), lower education level (p = 0.006), lower monthly income (p = 0.036), metastatic cancer (p = 0.001), lower EQ-VAS score (p<0.001), and more severe level of distress (p<0.001). Conclusions Our findings showed a significant decrement in utility scores among metastatic breast cancer patients. Patients’ health-state utility differed by their demographic characteristics (age, education level, and income) and clinical characteristics (stage of cancer and distress). Their utility scores may support further cost-effectiveness analysis in Vietnam.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study

Luu,

Dinh,

Tran

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…En este estudio se identificó que la afectación en imagen corporal fue similar (p = 0,07) entre el grupo con manejo activo (47,5 puntos) y el grupo postratamiento (53,4 puntos), sin embargo, se evidenció que existe una peor imagen corporal (p <0,001) en estos grupos respecto a las mujeres de la población general (70,2 puntos). De igual forma, en el estudio multicéntrico, prospectivo y observacional de Monteiro et al (20) en 250 mujeres mayores de 28 años, con diagnóstico de cáncer de mama invasivo o in situ, sin manejo sistémico ni radioterapia previos evaluaron la afectación de la calidad de vida y percepción de la imagen corporal durante los primeros doce meses de tratamiento, y encontraron que los primeros seis meses en aquellas pacientes con quimioterapia sistémica fue el tiempo en que ellas puntuaron más bajo la imagen corporal, lo que hace considerar una relación altamente significativa con la afectación en la calidad de vida (p = 0,0001).…”

Section: Eortc Qlq Br23unclassified

Imagen corporal, cáncer de mama y su relación con la calidad de vida de las pacientes oncológicas: una revisión sistemática

Ávila Bareño,

Blanco Granados,

Ángel Buitrago

et al. 2024

Rev. Med.

View full text Add to dashboard Cite

Introducción: Dado que la imagen corporal constituye un eje transversal en la calidad de vida de la paciente oncológica, es de gran relevancia identificar su impacto en la misma, reconocer su importancia dentro del proceso de salud-enfermedad e incluirla en el abordaje y seguimiento, con el fin de mejorar su calidad de vida. Metodología: Se realizó una revisión ampliada de la literatura en bases de datos de libre acceso como Pubmed, bvs, Dialnet y Clinicalkey, entre agosto y septiembre de 2022; para ello se utilizaron términos MeSH como “cáncer de mama”, “imagen corporal” y “calidad de vida”, en inglés y español, y se relacionaron con el operador booleano “and”, en inglés, e “y”, en español. Resultados: Se seleccionaron 35 artículos, de los cuales 2 utilizaban la eortc qlq c30, 7 utilizaban la encuesta eortc qlq-br23 4 utilizaban bis como única escala. Por otra parte, 17 utilizaban la qlq-br23 y qlq c30, un artículo utilizó qlq-br23 y bis, y solo 4 utilizaban las tres escalas. Conclusiones: Es importante realizar un manejo individualizado en las pacientes con cáncer de mama, teniendo en cuenta que su imagen corporal se ve afectada de manera negativa, lo cual influye en su calidad de vida. Respecto al manejo quirúrgico se determinó que las pacientes sometidas a mastectomía presentan mayor afectación en la percepción de su imagen corporal. Finalmente, en las pacientes manejadas con quimioterapia se evidencia deterioro de la imagen corporal conforme avanza el tratamiento, la caída de cabello representa para ellas una gran preocupación.

show abstract

Patient‐reported outcome and survival in premenopausal hormone receptor‐positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real‐world study

Yang,

Gan,

Luo

et al. 2024

MedComm

View full text Add to dashboard Cite

Toremifene, a selective estrogen receptor modulator, is commonly used in China for premenopausal breast cancer patients. This real‐world study aimed to compare patient‐reported outcome (PRO) and survival between toremifene and aromatase inhibitor (AI) plus ovarian function suppression (OFS) in patients with moderate‐/high‐risk premenopausal hormone receptor (HR)‐positive breast cancer. The primary endpoint was PROs, assessed using SF‐36 and EQ‐5D‐5L questionnaires between January and March 2023. A total of 392 patients were included, with 171 receiving toremifene and 221 receiving AI. The toremifene group showed significantly higher scores in the role physical (p = 0.034) and mental health (p = 0.009) dimensions of SF‐36 and lower anxiety/depression (AD) scores (p = 0.038) in EQ‐5D‐5L compared to AI group. The estimated 5‐ and 8‐year disease‐free survival (DFS) rates were similar in toremifene and AI groups: 96.5% versus 91.9%, and 87.4% versus 87.8% (p = 0.39), respectively. Adverse event rates were similar in two groups, except for a greater risk of endometrial thickening (p < 0.001) and a lower occurrence of morning stiffness (p < 0.001) in the toremifene compared to the AI group. Premenopausal HR‐positive breast cancer patients receiving toremifene plus OFS had better role physical and mental health outcomes and lower AD dimensions than those receiving AI plus OFS. Both treatments had comparable DFS and favorable tolerability profiles.

show abstract

Patient-centered Outcomes in Breast Cancer: Description of EQ-5D-5L and EORTC-QLQ-BR23 Measurements in Real-world Data and Their Association With Survival

Cited by 6 publications

References 23 publications

Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study

Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study

Imagen corporal, cáncer de mama y su relación con la calidad de vida de las pacientes oncológicas: una revisión sistemática

Patient‐reported outcome and survival in premenopausal hormone receptor‐positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real‐world study

Contact Info

Product

Resources

About